$0.76
0.01[1.33%]
Last update: 6:42PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$0.76
0[0.00%]
| Open- | Close- |
| Vol / Avg.0 / 535.699K | Mkt Cap171.891M |
| Day Range- - - | 52 Wk Range0.680 - 2.645 |
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%
Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Key Statistics
Adaptimmune Therapeutics Stock (NASDAQ: ADAP) analysis, key statistics.
Valuation Measures
Enterprise Value
-8.7M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
1.8
Price / Book (mrq)
1.34
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.56
Tangible Book value per share
0.56
Total Liabilities (Quarterly)
216.3M
Total Assets
343M
Total Liabilities
216.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-416.94%
EBIT Margin
-875.4%
EBITDA Margin
-831.89%
Operating Margin
-875.4%